Immunization with Virus-Like Particle of Human Papillomavirus Type 16 L1 Elicits CTL Immune Response in C57BL/6 Mice


Article Preview

The development of a human papillomavirus vaccine has received a lot of recent attentiondue to the connection between HPV infections and cervical cancer. One promising vaccine to prevent HPV infections is an HPV virus-like particle, and various studies have already shown that HPV VLP immunization elicits a humoral immune response. However, cell mediated immunity is important for the prevention of HPV infections and cancer therapy. Therefore, to check the elicitation of a CTL response by yeast-derived virus- like particles consisting of the HPV16 capsid protein L1, HPV16 L1 VLPs were produced and purified, then C57BL/6 mice immunized with the HPV16 L1 VLPs by subcutaneous injection. Thereafter, the splenocytes from the immunized mice were isolated and a chromium release assay performed using recombinant B16/HPV16 L1cells constantly expressing the HPV16 L1 protein. As a result, the data demonstrated that the T cells from the HPV16 L1 VLP immunized mice exhibited a significantly higher cytotoxic T lymphocyte activity against the recombinant B16/HPV16 L1 cells than the T cells from the PBS immunized control mice.



Key Engineering Materials (Volumes 277-279)

Edited by:

Kwang Hwa Chung, Yong Hyeon Shin, Sue-Nie Park, Hyun Sook Cho, Soon-Ae Yoo, Byung Joo Min, Hyo-Suk Lim and Kyung Hwa Yoo




H. M. Pyo et al., "Immunization with Virus-Like Particle of Human Papillomavirus Type 16 L1 Elicits CTL Immune Response in C57BL/6 Mice ", Key Engineering Materials, Vols. 277-279, pp. 119-124, 2005

Online since:

January 2005




[1] Zhou, J., X. Y. Sun, H. Davies, L. Crawford, D. Park, and I. H. Frazer: Virology. Vol. 189 (1992), pp.592-599.

[2] Zur Hausen, H: Biochim. Biophys. Acta Vol. 1288 (1996), p. F55-78. Title of Publication (to be inserted by the publisher).

[3] Kirnabauer R, Booy F, Cheng N, Lowy DR, and Schiller JT: Proc. Natl. Acad. Sci. USA Vol. 89 (1992), pp.12180-12184.

[4] Kirnabauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, and Schiller JT: J. Virol. Vol. 67 (1993), pp.6929-6936.

[5] Hagensee ME, N. Yaegashi, and D. A. Galloway: J. Virol. Vol. 67 (1993), pp.315-322.

[6] Li M., T. P. Cripe, P. A. Estes, M. K. Lyon, R. C. Rose, and R. L. Garcea: J. Virol. Vol. 71 (1997), pp.2988-2995.

[7] Hofmann, K. J., J. C. Cook, J. G. Joyce, D. R. Brown, L. D. Schultz, H. A. George, M. Rosolowsky, K. H. Fife, and K. U. Jansen: Virology. Vol. 209 (1995), pp.506-518.

[8] Nardellihaefliger, D., R. Roden, J. Benyacoub, R. Sahli, J. P. Kraehenbuhl, J. T. Schiller, P. Lachat, A. Potts, and P. Degrandi: Infect. Immun. Vol. 65 (1997), pp.3328-3336.

[9] Ssagawa T, P. Pushko, G. Steers, S.E. Gshmeissner, M.A.N. Hajibagheri, J. Finch, L. Crawford, and M. Tommasino: Virology. Vol. 206 (1995), pp.126-135.

[10] Schiller JT, Lowy DR: J. Natl. Cancer Inst. Monogr. Vol. 28 (2001), pp.50-54.

[11] Schiller JT: Mol. Med. Today Vol. 5 (1999), pp.209-215.

[12] Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: J. Natl. Cancer Inst. Vol. 87 (1995), pp.796-802.

[13] Cornelison TL: Curr. Opin. Oncol. Vol. 12-5 (2000), pp.466-73.

[14] Parkin DM, P. Pisani, and J. Ferlay: Int. J. Cancer Vol. 80 (1999), pp.827-841.

[15] Stanley MA: Curr. Opin. Mol. Ther. Vol. 4-1(2002), pp.15-22.

[16] Stanley MA: Expert Rev Vaccines. Vol. 2-3 (2003), pp.381-389.

[17] Harro C.D., Y. Y. Pang, R. B. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, and D. R. Lowy: J. Natl. Cancer Inst. Vol. 93 (2001), pp.284-292.


[18] Koutsky L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barrm F. B. Alvarez, L. M. Chiacchierini, and K. U. Jansen: N. Engl. J. Med. Vol. 347 (2002), pp.1645-1651.

[19] Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P: J. Natl. Cancer Inst. Vol. 95-15 (2003), pp.1128-1137.


[20] Jie-Yun Park, Hyun-Mi Pyo, Sun-woo Yoon, Sun-Young Baek, Sue-Nie Park, Chul-Joong Kim, and Haryoung Poo: J. Microbiol. Vol. 40 (2002), pp.313-318.

[21] Balmelli C, Roden R, Potts A, Schiller JT, De Grandi P, Nardelli-Haefliger D: J. Virol. Vol. 72 (1998), pp.8220-8229.

[22] Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL: Vaccine Vol. 23 (1999), pp.2129-2135.

[23] Kirnbauer R, LM Chandrachud, BW Oneil, ER Wagner, GJ Grindlay, A Armstrong, GM Mcgarvie, JT Schiller, DR Lowy, and MS Campo: Virology. Vol. 219 (1996), pp.37-44.


[24] Rose RC, Reichmann RC, and Bonnez W: J. Gen. Virol. Vol. 75 (1994), p.2075-(2079).

[25] Roden R.B.S., H.L. Greenstone, R. Kirnabauer, J.P. Booy, J. Jessie, DR Lowy, and JT Schiller: J. Virol. Vol. 70 (1996), pp.5875-5883. Title of Publication (to be inserted by the publisher).

[26] Lowe R. S., D. R. Brown, J. T. Bryan, J. C. Cook, H. A. George, K. J. Hofmann, W. M. Hurni, J. G. Joyce, E. D. Lehman, H. Z. Markus, M. P. Neeper, L. D. Schiltz, A. R. Shaw, and K. U. Jansen: J. Infect. Dis. Vol. 176 (1997), pp.1141-1145.

[27] Peng S, Frazer IH, Fernando GJ, Zhou J: Virology. Vol. 240-1 (1998), pp.147-157.

[28] Maurizio Chiriva-Internati, Young Liu, Emanuela Salati, Weiping Zhou, Zhiqing Wang, Fabio Grizzi, Juan J. Roman, Seah H. Lim, and Paul L. Hermnoat: Eur. J. Immonol. Vol. 32 (2002), pp.30-38.


[29] Marion Nonn, Manuela Schinz, Klaus Zumbach, Michael Pawlita, Achim Schneider, Matthias Dürst, and Andreas M. Kaufmann: J. Cancer Res. Clin. Oncol. Vol. 129 (2003), pp.511-520.


[30] Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH: Virology. Vol. 273-2 (2000), pp.374-382.

[31] Peter Öhlschläger, Wolfram Osen, Kerstin Dell, Stefan Faath, Robert L. Garcea, Ingrid Jochmus, Martin Müller, Michael Pawlita, Klaus Schäfer, Peter Sehr, Caroline Staib, Gerd Sutter, and Lutz Gissmann: J. Virol. Vol. 77 (2003), pp.4635-4645.